iTeos Therapeutics, Inc. (NASDAQ:ITOS – Get Rating) – Wedbush reduced their Q2 2023 EPS estimates for shares of iTeos Therapeutics in a note issued to investors on Wednesday, May 10th. Wedbush analyst D. Nierengarten now expects that the company will earn ($0.73) per share for the quarter, down from their prior estimate of ($0.58). Wedbush […]
iTeos Therapeutics (NASDAQ:ITOS – Get Rating) and Fennec Pharmaceuticals (NASDAQ:FENC – Get Rating) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, dividends, earnings, profitability and risk. Volatility and Risk iTeos Therapeutics has a beta of […]
Fennec Pharmaceuticals (NASDAQ:FENC – Get Rating) and iTeos Therapeutics (NASDAQ:ITOS – Get Rating) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, dividends, analyst recommendations, earnings, institutional ownership, risk and valuation. Risk & Volatility Fennec Pharmaceuticals has a beta of […]
Equities analysts expect that iTeos Therapeutics, Inc. (NASDAQ:ITOS – Get Rating) will report earnings per share (EPS) of $1.20 for the current quarter, according to Zacks Investment Research. Four analysts have made estimates for iTeos Therapeutics’ earnings, with the lowest EPS estimate coming in at $0.08 and the highest estimate coming in at $3.13. iTeos […]
Wall Street brokerages expect that iTeos Therapeutics, Inc. (NASDAQ:ITOS – Get Rating) will announce $63.30 million in sales for the current fiscal quarter, Zacks Investment Research reports. Four analysts have made estimates for iTeos Therapeutics’ earnings, with estimates ranging from $40.00 million to $78.10 million. The business is scheduled to issue its next earnings results […]